

# Simultaneous Analysis of Multidrug Resistance 1(MDR1) C3435T, G2677T/A, and C1236T Genotypes in Hamadan City Population, West of Iran

Massoud Saidijam<sup>1,2</sup>, Hossein Mahjub<sup>3</sup>, Nooshin Shabab<sup>1,2</sup> and Reza Yadegarazari<sup>\*1,2</sup>

<sup>1</sup>Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran;

<sup>2</sup>Dept. of Genetic and Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran;

<sup>3</sup>Dept. of Biostatistics and Epidemiology and Research Center for Health Sciences, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran

Received 5 April 2014; revised 18 May 2014; accepted 19 May 2014

## ABSTRACT

**Background:** One of the limitations in the treatment of common diseases such as cancer chemotherapy is development of multidrug resistance (MDR). Polymorphisms could alter the expression level of *MDR1* gene, which plays an important role in MDR. In this research, the frequency of C3435T, C1236T, and G2677T/A polymorphisms of *MDR1* gene was investigated in a large group of population from Hamadan city to provide a sample data resource. **Methods:** Peripheral blood (2 ml) was taken, and DNA extraction was carried out. Multiplexed mutagenically separated PCR, which was followed by polyacrylamide gel electrophoresis and silver staining, was applied to detect the mentioned polymorphisms in 935 individuals. Sequencing performed for confirmation of gel electrophoresis resulted in 10 random cases. In total, alleles and genotypes of 933 persons (776 women and 157 men) were determined. **Results:** The most frequent alleles of the polymorphisms were: 3435T, C1236, and G2677. The most frequent genotypes were: 3435C/T, 1236C/T, and 2677G/A, and their concurrent presence was also found as the most frequent simultaneous genotypes. There was not any meaningful difference among the prevalence of these genotypes in groups of men and women. **Conclusion:** Our results were close to those of other studies performed in Iran and compared to the other ethnic groups, which showed more similarity to Asian peoples than Europeans. As an aspect of personalized medicine, it could be used by chemotherapists to improve the routine methods of cancer treatment. *Iran. Biomed. J. 19 (1): 57-62, 2015*

**Keywords:** Gene polymorphism, Multi-drug resistance, Neoplasm

## INTRODUCTION

The multidrug resistance 1 (MDR1) gene product, P-glycoprotein (P-gp), belongs to a family of ABC membrane transporters. This gene product is responsible for the cellular efflux of a variety of drugs and cellular metabolites across the plasma membrane and reduces exposure to potentially toxic compounds of intracellular environment [1-3]. Despite the advantage, this function results in resistance to a broad spectrum of drug effects, which in turn rises the side effects and costs of medical treatment of many important diseases in the field of general health e.g. cancers. The broad range of chemical transport affected by P-gp function consists of cancer chemotherapy and immuno-suppression agents and of drugs used in hypertension, allergy, infection, neuro-

logy, and inflammation [4].

The *MDR1* is a highly polymorphic gene, composed of 28 exons with a variety of single nucleotide polymorphisms (SNP) [5, 6]. Relationship between a few *MDR1* gene polymorphisms, presumably affects the P-gp function, and drug resistance has been studied in common malignancies, including lung [7, 8], breast [9, 10], colorectal [11], and gastric [12] cancers. Cancer risk may also be altered in the presence of these genetically predisposing factors [13]. Additionally, relationship between *MDR1* gene characteristics and gastric induced *Helicobacter pylori* infection [14] and also human immunodeficiency virus-1 infection [15] emphasizes the noteworthy function of *MDR1* gene in all steps of prevention and treatment of diseases.

\*Corresponding Author; Mobile: (+98-918) 8326896; Fax: (+98-811) 8380208; E-mail: reza.yadegarazari@yahoo.com

**Table 1.** Sequence and amounts of primers used for mutagenically separated PCR assays on multidrug resistance 1 (MDR1) gene three polymorphisms

SNP alleles		F primer (amount of use*)	Common R primer (amount of use*)	Amplicon length (bp)
G2677T/A	G	GAT AAG AAA GAA CTA GAG GGT G (1)	GAA AAA GAT TGC TTT GAG	161
	A	GAC AAG ATC TGA AAT AAA AGA AAG AAC TAG TAG GTA (10)	GAA TGG (5)	175
	T	CAC TGA AAA TAA AGA AAG AAC TAG AAT GTT(10)		169
C3435T	C	GGT GTC ACA GGA AGA GAT C (1)	GGC CAG AGA GGC TGC	126
	T	CAG CCG GGT ATA GTC ACA GGA AGA TAT T (1)	CAC AT(1)	135
C1236T	C	CCT GGT AGA TCT TGA ACG GC (2)	GCA TCA GCT GGA CTG	105
	T	CTC ACT CGT AAA GGT AGA TCT TGA AGA GT (20)	TTG TG (20)	114

\*, amount of use = picomol

C3435T polymorphism in exon 26 of *MDR1* gene has a significant correlation with the P-gp expression level [16]. G2677T/A in exon 21 and C1236T in exon 12 are also other important polymorphisms of the gene. Bioavailability of many drugs may be influenced by these variants of *MDR1* because of alteration in pharmacokinetics and pharmacodynamics of the drug [17]. However, functional significance of these polymorphisms of ABC membrane transporters has not been carefully understood; therefore, considering a particular SNP to predict individual's pharmacokinetics is not feasible.

Pattern of *MDR1* polymorphisms differs among populations and races. Prediction of drug resistance and also an appropriate decision for medical treatment of many diseases are important results of studying these polymorphisms. Another aspect of importance of related studies is understanding the role of P-gp function in process such as apoptosis and immune responses [18]. Relationship of the polymorphisms of *MDR1* gene and a few of diseases has been investigated in Iran [19, 20].

In this investigation, we decided to determine the frequencies of C1236T, G2677T/A, and 3435T *MDR1* gene alleles and genotypes in a large population from Hamadan city of Iran, which provides a primary data resource. These data help the clinicians to estimate the probability of vulnerability to many diseases and resistance to some of the important drugs, especially cancers and anti-cancer agents.


## MATERIALS AND METHODS

**Study group and sampling.** The study group consisted of randomly chosen 935 recipients of primary health care, admitted to health centers of Hamadan city, Iran. The protocol was approved by Ethics Committee of Hamadan University of Medical Sciences prior to the study. The research was carried

out according to the principles set out based on the Declaration of Helsinki 1964 and all subsequent revisions. After a brief explanation of study purpose and taking an informed consent, 2 ml peripheral venous blood was collected in sodium EDTA (as anti-coagulant)-containing tubes, kept on ice and transferred to laboratory. Then, the final results of the study on 933 individuals were reported.

**PCR analysis.** DNA extraction kit (CinnaGen, Iran) was applied for DNA extraction according to the manufacturer's instructions. The *MDR1* SNP (C3435T, G2677T/A, and C1236T) profile was determined by a mutagenically separated PCR protocol. Allele-specific primers for each SNP were designed according to this protocol (Table 1). PCR amplification product lengths were different in various types of alleles [21] (Table 1). Advantages of the technique were as minimizing cross-reactions between primers and PCR products in ongoing cycles as well as simultaneous analysis of three genotypes of considered gene [22]. Primer efficacy was checked by preliminary tests on positive and negative controls. The reaction mixture contained 4 ng genomic DNA as template, 2  $\mu$ M each dNTP, 1.5 mmol/l MgCl<sub>2</sub>, 0.5 unit of Taq polymerase, 3  $\mu$ l PCR buffer 10 $\times$ , and primers (as presented in Table 1). PCR cycles were: 1) early denaturation period of 10 min at 95°C, 2) 35 cycles of denaturation at 95°C for 45 s, annealing at 49°C for 45 s, and elongation at 72°C for 45 s, and 3) final extension at 72°C for 1 min.

**Gel electrophoresis.** Detection of PCR products was carried out by subjecting the products to gel electrophoresis on pre-cast 20% TBE polyacrylamide gels at 90 V overnight and visualized by silver nitrate staining. Exposure to visible light and digital imaging was applied for revealing the amplicon bands and calculating their sizes compared to the standard ladder. Detection of bands with expected size (Table 1) was considered as positive result.



**Fig. 1.** Polyacrylamide gel (20%) results after mutagenically separated PCR assays on multidrug resistance 1 (MDR1) gene C1236T, 3435T, and G2677T/A polymorphisms. Columns no. 1 and 6 show 50 bp and 100 bp ladder, respectively. Others show the detected bands of samples. The numbers indicate: allele C1236T (105 bp), allele C3435T (114 bp), allele C1236T (126 bp), allele C3435T (135 bp), allele G2677T/A (161 bp), allele G2677T/A (169 bp), allele G2677T/A (175 bp) and ladders bands.

**Sequencing analysis.** Sequencing analysis was performed by Bioneer Corporation (Korea) on randomly chosen 10 PCR products.

**Statistical analysis.** The sample size (n) was calculated based on results of allele and genotype frequencies for MDR1 SNP in similar studies using the following formula with prevalence (P) = 40% and difference (d) = 10%. The results were multiplied in 1.5 (as effect design) for calculation of final sample size.

$$n = \frac{(1.96)^2 P(1-P)}{d^2}$$

SPSS software (version 10) was used to calculate the frequencies of SNP. Two-sample binomial test was used to compare the results of frequencies. A P value <0.05 was considered as significant difference.

## RESULTS

Samples obtained from 933 individuals (157 males and 776 females) were analyzed. As mentioned in the previous section, in mutagenically separated PCR technique, making concurrent assay of several polymorphisms is possible. Figure 1 demonstrates an example of gel electrophoresis results. For any case, separate bands had been detected to reveal its polymorphism profile.

Results of allele and genotype profiling are presented in Table 2. Statistical analysis of the results showed that:


1. For SNP G2677T/A, allele G was the most frequent one and a meaningful difference was observed between the frequency of this allele and allele A ( $P=0.036$ ) and T ( $P<0.001$ ). In the case of genotypes, G2677A had a frequency more than the other studied genotypes ( $P<0.001$ ).
2. For SNP C3435T, allele T showed a frequency more than allele C with no meaningful differences ( $P=0.293$ ). In the case of genotypes, C3435T had a frequency more than the two other homozygous genotypes ( $P<0.001$ ).
3. For SNP C1236T, allele C had a frequency more than allele T with meaningful differences ( $P<0.001$ ). In the case of genotypes, C3435T had a frequency more than the other two genotypes ( $P<0.001$ ).

For assessment of concurrent presence of MDR1 C3435T, G2677T/A, and C1236T polymorphisms, the most frequent genotype in each SNP group was considered, and the rates of their simultaneous presence were calculated (Table 3). As shown in Table 3, the most frequent case was concurrent presence of all of them.

Frequency of most common genotype in each group was also evaluated according to individuals' gender. The parameter was statistically equal between men and women in all three genotypes (Table 4).

**Table 2.** Allele and genotype prevalence of multidrug resistance 1 (MDR1) gene polymorphisms in 933 individuals of Hamadan city population

SNP	Allele frequency (%)			Genotype frequency (%)					
	G	A	T	GG	GA	GT	AA	AT	TT
G2677T/A	815 (43.7)	752 (40.3)	299 (16)	150 (16.1)	429 (46)	86 (9.2)	76 (8.1)	171 (18.3)	21 (2.3)
C3435T	917 (49.1)	949 (50.9)		CC 165 (17.7)	CT 587 (62.9)	TT 181 (19.4)			
C1236T	1192 (63.9)	674 (36.1)		CC 295 (31.6)	CT 602 (64.5)	TT 36 (3.9)			



**Fig. 2.** Sequencing results of mutagenically separated PCR products of multidrug resistance 1 (*MDR1*) gene C1236T, 3435T, and G2677T/A polymorphisms. rev, reverse sequencing.

**Sequencing results.** Sequencing analysis on 10 random chosen PCR products from different cases confirmed the accuracy of gel electrophoresis findings of PCR (Fig. 2).

## DISCUSSION

Drug resistance is a common and vital challenge in the field of internal medicine. P-gp, the product of the *MDR1* gene, plays an important role in the bioavailability of many medications with a narrow therapeutic window such as anti-cancer agents and cardiovascular drugs [22]. This phenomenon is the most common genetic mechanism of resistance to treatment with anti-cancer drugs. Many important data have been released from several investigations about the mechanism of P-gp function and pharmacokinetics of many commonly used drugs for circumventing this resistance and improving cancer chemotherapy [23]. Therefore, the function of human *MDR1* gene may be

**Table 3.** Concurrent presence of 3 most frequent genotypes of multidrug resistance 1 (*MDR1*) gene in 933 individuals of Hamadan city population

Genotype	C3435T +	C3435T -	C3435T +	C3435T -
	C1236T -	C1236T +	C1236T +	C1236T -
G2677A +	92	96	196	45
G2677A -	117	128	182	77

Plus and minus signs indicate for individuals with or without studied genotypes, respectively.

judged as a positive marker with ability to transforming human cells to MDR. Many hydrophobic anti-cancer agents have been shown the degrees of ineffectiveness due to this mechanism [24, 25]. Additionally, elevated levels of *MDR1* RNA have been reported in many untreated cancers [26]. In some different neoplasms, the same condition has been described at relapse of the disease after chemotherapy [26].

More than one hundred SNP have been recognized in the human *MDR1* gene [27]. The most important are C3435T, C1236T, and G2677A, T SNP. In the present study, we decided to determine the prevalence of these functionally important SNP in a large population to provide valuable information for optimizing the individualized therapeutic approach especially for anti-cancer treatment.

In the case of C3435T, the most studied polymorphism in cancers, the frequency of heterozygote genotype (C3435T) was more than two other genotypes in both male and female subjects. The same results have been also released from similar recent studies in Iran [19, 28-30]. Result of a study in Japan on 154 healthy Japanese and 100 healthy Caucasians showed the same result for genotypes in Japanese but a more frequency of genotype T3435T in Caucasians [31] and this study. The frequency of genotype T3435T has been also shown to be higher in Germany and Serbian ethnics [22, 32]. In total, it seems that the pattern of SNP of C3435T polymorphism in Iran resembles to Asian peoples in comparison to Europeans. The expression of *MDR1* gene and the probability of drug resistance have been shown to be

**Table 4.** Comparison of prevalence of 3 most frequent genotypes of multidrug resistance 1 (MDR1) gene between men and women in 933 individuals of Hamadan city population

Sex \ Genotype	2677G/A (%)	3435C/T (%)	1236C/T (%)
males	82 (52.2)	98 (62.4)	112 (71.3)
females	347 (44.7)	489 (63)	490 (63.1)
P value	0.085	0.888	0.051

lower in carriers of genotype T3435T than C3435C [21, 33]. However, recent meta-analysis studies have affirmed that presence of T3435T genotype correlates with increase in the risk of colorectal cancer and acute lymphoblastic leukemia [13, 34].

Allele G2677 and genotype G2677A were more prevalent in G2677A/T polymorphism than the others. Results for the mentioned allele were similar to Japanese, Caucasians, and Serbians with small differences, but genotype frequencies, in this study, had a significant difference with the last two mentioned groups [22, 31]. Unexpectedly, similar investigations in Iran showed dissimilar findings [28, 30]. Overall risk of cancers increases in individuals with TT, AT, and AA genotypes, especially Asian populations [34]. In C1236T group, genotype C1236T was more common than the other genotypes in our study, which was similar to Japanese, Caucasians, and Serbians [22, 31]. However, the more frequency of allele C than T is different from the results of many other studies but for Serbian people. Not so many information has been released regarding to the prevalence of C1236T genotype, and also no correlation between this genotype and cancer has been found [34].

Function of membrane transporter such as *MDR1* was affected by special mutations, which may be considered as a predictive marker in both the risk of diseases and their mortality and morbidity [16-19]. Therefore, the evaluation of the prevalence of these SNP in the present study and ongoing researches in other countries and populations would induce new concepts about investigation in the field of personalized medicine and could be applied as a primary data for this purpose. Additionally, the participants of such studies may be the subjects of future ante-grade cohort researches for assessment of risk ratios of many important diseases.

#### ACKNOWLEDGEMENTS

This work was supported by Research and Technology Deputy of Hamadan University of Medical Sciences. We thank the staffs of health centers of Hamadan city.

#### REFERENCES

- Bodor M, Kelly EJ, Ho RJ. Characterization of the human MDR1 gene. *AAPS J.* 2005 Feb; 7(1):E1-5.
- Allikmets R, Gerrard B, Hutchinson A, Dean M. Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. *Hum Mol Genet.* 1996 Oct; 5(10):1649-55.
- Yamada O, Ozaki K, Furukawa T, Machida M, Wang YH, Motoji T, et al. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. *Cell Signal.* 2011 Jul; 23(7):1119-27.
- Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. *Clin Pharmacol Ther.* 2004 Jan; 75(1):13-33.
- Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoprotein. *J Biol Chem.* 1990 Jan; 265(1):506-14.
- Ishikawa T, Hirano H, Onishi Y, Sakurai A, Tarui S. Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. *Drug Metab Pharmacokin.* 2004 Feb; 19(1):1-14.
- Wei HB, Hu J, Shang LH, Zhang YY, Lu FF, Wei M, et al. A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer. *Chin Med J (Engl).* 2012 Aug; 125(16):2902-7.
- Dogu GG, Kargi A, Turgut S, Ayada C, Taskoylu BY, Demiray G, et al. MDR1 single nucleotide polymorphism C3435T in Turkish patients with non-small-cell lung cancer. *Gene.* 2012 Sep; 506(2):404-7.
- George J, Dharanipragada K, Krishnamachari S, Chandrasekaran A, Sam SS, Sunder E. A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. *Clin Breast Cancer.* 2009 Aug; 9(3):161-5.
- Cizmarikova M, Wagnerova M, Schonova L, Habalova V, Kohut A, Linkova A, et al. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. *Pharmacogenomics J.* 2010 Feb; 10(1):62-9.
- Paule B, Castagne V, Picard V, Saffroy R, Adam R, Guettier C, et al. MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan

- refractory colorectal cancer. *Med Oncol.* 2010 Dec; 27(4):1066-72.
12. Li Y, Yan PW, Huang XE, Li CG. MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. *Asian Pac J Cancer Prev.* 2011 Dec; 12(9):2405-9.
  13. Sheng X, Zhang L, Tong N, Luo D, Wang M, Xu M, et al. MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case-control studies. *Mol Biol Rep.* 2012 Jul; 39(7):7237-49.
  14. Tahara T, Shibata T, Yamashita H, Yoshioka D, Hirata I, Arisawa T. Promoter methylation status of multidrug resistance 1 (MDR1) gene in noncancerous gastric mucosa correlates with *Helicobacter pylori* infection and gastric cancer occurrence. *Cancer Invest.* 2010 Aug; 28(7):711-6.
  15. Gupta S, Gollapudi S. P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection. *J Clin Immunol.* 1993 Sep; 13(5):289-301.
  16. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. *Cancer Res.* 2002 Sep; 62(17):4955-62.
  17. Cascorbi IKH, Siegmund W. Pharmacogenetics of P-gp mediated drug transport. *Acta Leopold.* 2003 Sep; 329:93-100.
  18. Pawlik A, Fiedorowicz-Fabrycy I, Gawronska-Szklarz B. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. *Int J Clin Pharmacol Ther.* 2004 Sep; 42(9):496-503.
  19. Taheri M, Mahjoubi F, Omranipour R. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. *Genet Mol Res.* 2010 Jan; 9(1):34-40.
  20. Sabahi Z, Salek R, Heravi RE, Mosaffa F, Avanaki ZJ, Behravan J. Association of gastric cancer incidence with MDR1 gene polymorphism in an ethnic Iranian population. *Indian J Cancer.* 2010 Jul-Sep; 47(3):317-21.
  21. Sunder-Plassmann R, Rieger S, Endler G, Brunner M, Muller M, Mannhalter C. Simultaneous analysis of MDR1 C3435T, G2677T/A, and C1236T genotypes by multiplexed mutagenically separated PCR. *Clin Chem Lab Med.* 2005 Feb; 43(2):192-4.
  22. Milojkovic M, Stojnev S, Jovanovic I, Ljubisavljevic S, Stefanovic V, Sunder-Plassman R. Frequency of the C1236T, G2677T/A and C3435T MDR1 gene polymorphisms in the Serbian population. *Pharmacol Rep.* 2011 May-Jun; 63(3):808-14.
  23. Gottesman MM. Mechanisms of cancer drug resistance. *Annual Rev Med.* 2002 Feb; 53:615-27.
  24. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. *Biochim Biophys Acta.* 1976 Nov; 455(1):152-62.
  25. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. *Proc Natl Acad Sci USA.* 1987 May; 84(9):3004-8.
  26. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, et al. Expression of a multidrug resistance gene in human cancers. *J Natl Cancer Inst.* 1989 Jan; 81(2):116-24.
  27. Maeda K SY. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. *Drug Metab Pharmacokinet.* 2008; 23:223-35.
  28. Sayyah M, Kamgarpour F, Maleki M, Karimipour M, Gharagozli K, Shamshiri AR. Association analysis of intractable epilepsy with C3435T and G2677T/A ABCB1 gene polymorphisms in Iranian patients. *Epileptic Disord.* 2011 Jun; 13(2):155-65.
  29. Khedri A, Nejat-Shokouhi A, Salek R, Esmaeili H, Mokhtarifar A, Entezari Heravi R, et al. Association of the colorectal cancer and MDR1 gene polymorphism in an Iranian population. *Mol Biol Rep.* 2011 Jun; 38(5):2939-43.
  30. Samanian S, Mahjoubi F, Mahjoubi B, Mirzaee R, Azizi R. MDR1 gene polymorphisms: possible association with its expression and clinicopathology characteristics in colorectal cancer patients. *Asian Pac J Cancer Prev.* 2011 Dec; 12(11):3141-5.
  31. Komoto C, Nakamura T, Sakaeda T, Kroetz DL, Yamada T, Omatsu H, et al. MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. *Drug Metab Pharmacokinet.* 2006 Apr; 21(2):126-32.
  32. Hitzl M, Drescher S, van der Kuip H, Schaffeler E, Fischer J, Schwab M, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. *Pharmacogenetics.* 2001 Jun; 11(4):293-8.
  33. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, John A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity *in vivo*. *Proc Natl Acad Sci USAmerica.* 2000 Mar; 97(7):3473-8.
  34. Wang LH, Song YB, Zheng WL, Jiang L, Ma WL. The association between polymorphisms in the MDR1 gene and risk of cancer: a systematic review and pooled analysis of 52 case-control studies. *Cancer Cell Int.* 2013 May; 13(1):46.